| A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis JD Kessler, KT Kahle, T Sun, KL Meerbrey, MR Schlabach, EM Schmitt, ... Science 335 (6066), 348-353, 2012 | 454 | 2012 |
| Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8 ZC Hartman, GM Poage, P Den Hollander, A Tsimelzon, J Hill, ... Cancer research 73 (11), 3470-3480, 2013 | 442 | 2013 |
| Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications ZC Hartman, DM Appledorn, A Amalfitano Virus research 132 (1-2), 1-14, 2008 | 314 | 2008 |
| Increasing vaccine potency through exosome antigen targeting ZC Hartman, J Wei, OK Glass, H Guo, G Lei, XY Yang, T Osada, ... Vaccine 29 (50), 9361-9367, 2011 | 219 | 2011 |
| T-Scan: a genome-wide method for the systematic discovery of T cell epitopes T Kula, MH Dezfulian, CI Wang, NS Abdelfattah, ZC Hartman, ... Cell 178 (4), 1016-1028. e13, 2019 | 180 | 2019 |
| Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo ZC Hartman, A Kiang, RS Everett, D Serra, XY Yang, TM Clay, ... Journal of virology 81 (4), 1796-1812, 2007 | 162 | 2007 |
| HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis ZC Hartman, XY Yang, O Glass, G Lei, T Osada, SS Dave, MA Morse, ... Cancer research 71 (13), 4380-4391, 2011 | 155 | 2011 |
| Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system A Kiang, ZC Hartman, RS Everett, D Serra, H Jiang, MM Frank, ... Molecular Therapy 14 (4), 588-598, 2006 | 112 | 2006 |
| The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity TJ Cohen, T Barrientos, ZC Hartman, SM Garvey, GA Cox, TP Yao The FASEB Journal 23 (1), 99, 2009 | 105 | 2009 |
| Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells ZC Hartman, EP Black, A Amalfitano Virology 358 (2), 357-372, 2007 | 98 | 2007 |
| CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis LC Tsao, EJ Crosby, TN Trotter, P Agarwal, BJ Hwang, C Acharya, ... JCI insight 4 (24), 2019 | 90 | 2019 |
| Mechanisms of therapeutic antitumor monoclonal antibodies LC Tsao, J Force, ZC Hartman Cancer research 81 (18), 4641-4651, 2021 | 86 | 2021 |
| Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors EJ Crosby, J Wei, XY Yang, G Lei, T Wang, CX Liu, P Agarwal, AJ Korman, ... Oncoimmunology 7 (5), e1421891, 2018 | 86 | 2018 |
| The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment J Turpin, C Ling, EJ Crosby, ZC Hartman, AM Simond, LA Chodosh, ... Oncogene 35 (47), 6053-6064, 2016 | 77 | 2016 |
| Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity T Osada, XY Yang, ZC Hartman, O Glass, BL Hodges, D Niedzwiecki, ... Cancer gene therapy 16 (9), 673-682, 2009 | 68 | 2009 |
| Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells JJ Barrott, PF Hughes, T Osada, XY Yang, ZC Hartman, DR Loiselle, ... Chemistry & biology 20 (9), 1187-1197, 2013 | 65 | 2013 |
| Death-associated protein kinase 1 promotes growth of p53-mutant cancers J Zhao, D Zhao, GM Poage, A Mazumdar, Y Zhang, JL Hill, ZC Hartman, ... The Journal of clinical investigation 125 (7), 2707-2720, 2015 | 64 | 2015 |
| Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study EJ Crosby, W Gwin, K Blackwell, PK Marcom, S Chang, HT Maecker, ... Clinical Cancer Research 25 (9), 2725-2736, 2019 | 60 | 2019 |
| Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA ES Gabitzsch, Y Xu, JP Balint, ZC Hartman, HK Lyerly, FR Jones Cancer Immunology, Immunotherapy 59, 1131-1135, 2010 | 55 | 2010 |
| Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors W Xia, Z Liu, R Zong, L Liu, S Zhao, SS Bacus, Y Mao, J He, JD Wulfkuhle, ... Molecular cancer therapeutics 10 (8), 1367-1374, 2011 | 54 | 2011 |
